BRAINTEASER: Special Session on “Artificial intelligence and statistical methods for neurodegenerative diseases” at the 17th Conference on Computational Intelligence Methods for Bioinformatics and Biostatistics (CIBB 2021)

On 15-17 November 2021, the 17th Conference on Computational Intelligence Methods for Bioinformatics and Biostatistics (CIBB 2021) will take place online.

In this context, the University of Padova (Padova, Italy), member of the BRAINTEASER Consortium, is organizing a special session titled “Artificial intelligence and statistical methods for neurodegenerative diseases”. The aim of this special session is to foster the synergistic interaction between advanced artificial intelligence and statistical methods, and clinical research in neurodegenerative diseases.

In the last decade, the digitalization of health data and the development of new sensing technologies have enormously increased the amount, variety and accessibility of health data. By leveraging medical big data, artificial intelligence (AI) and statistical methods have the potential to revolutionize the paradigm of healthcare, boosting the transition towards a proactive and continuously-learning healthcare system grounded on personalized and preventive medicine. In particular, big data and AI can help advance the knowledge about mechanisms driving the onset and the progression of neurodegenerative diseases, allowing the development of more effective and personalized prevention and treatment solutions.

This special session will gather state-of-the-art contributions about applications of advanced AI and statistical methods to neurodegenerative diseases, including big data analytics, models for clinical outcome prediction, patient stratification, feature extraction, data mining, and decision support systems.

Chairs of the session will be Erica Tavazzi, Martina Vettoretti, and Enrico Longato, three young researchers from University of Padova, directly involved in the development of AI models for predicting the progression of amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) within the BRAINTEASER project.

OUR NEWSLETTER

Upcoming Events

Latest posts

Skip to content